|
|
||||||||
Steroid-secreting human adrenocortical tumours are rare. Their incidence is estimated to be 0.2/100 000 per year (1). Benign adenomas and the malignant carcinomas are about equally frequent (2–4). The most common clinical presentation is that of Cushing's syndrome with or without association virilism. Adenomas responsible for primary aldosteronism (Conn's syndrome) are less frequent, and oestrogen-producing tumours—usually malignant— are rare (5). Approximately half the malignant adrenocortical cancers secrete mainly biosynthetic precursors with diminished bioactivity: their diagnosis is often delayed and they may thus be huge when discovered. More often sporadic, adrenocortical tumours can also combine with rare congenital syndromes including Beckwith-Wiedemann syndrome (6), the McCune-Albright syndrome (7) or Li-Fraumeni syndrome (8).
Because there are no absolute clinical, biological, anatomical or even histological criteria, in many cases the benign or malignant nature of a localized tumour cannot be strictly asserted. Malignant adrenocortical tumours have a very poor prognosis (2–4, 9–15): mean survival
This article has been cited by other articles:
![]() |
R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al. Gene Expression Profiling of Childhood Adrenocortical Tumors Cancer Res., January 15, 2007; 67(2): 600 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lampron, I. Bourdeau, P. Hamet, J. Tremblay, and A. Lacroix Whole Genome Expression Profiling of Glucose-Dependent Insulinotropic Peptide (GIP)- and Adrenocorticotropin-Dependent Adrenal Hyperplasias Reveals Novel Targets for the Study of GIP-Dependent Cushing's Syndrome J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3611 - 3618. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Libe and J. Bertherat Molecular genetics of adrenocortical tumours, from familial to sporadic diseases Eur. J. Endocrinol., October 1, 2005; 153(4): 477 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tissier, C. Cavard, L. Groussin, K. Perlemoine, G. Fumey, A.-M. Hagnere, F. Rene-Corail, E. Jullian, C. Gicquel, X. Bertagna, et al. Mutations of {beta}-Catenin in Adrenocortical Tumors: Activation of the Wnt Signaling Pathway Is a Frequent Event in both Benign and Malignant Adrenocortical Tumors Cancer Res., September 1, 2005; 65(17): 7622 - 7627. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Lefrancois-Martinez, J. Bertherat, P. Val, C. Tournaire, N. Gallo-Payet, D. Hyndman, G. Veyssiere, X. Bertagna, C. Jean, and A. Martinez Decreased Expression of Cyclic Adenosine Monophosphate-Regulated Aldose Reductase (AKR1B1) Is Associated with Malignancy in Human Sporadic Adrenocortical Tumors J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 3010 - 3019. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-H. Bernard, S. Sidhu, N. Berger, J.-L. Peix, D. J. Marsh, B. G. Robinson, V. Gaston, Y. Le Bouc, and C. Gicquel A Case Report in Favor of a Multistep Adrenocortical Tumorigenesis J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 998 - 1001. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gicquel, X. Bertagna, V. Gaston, J. Coste, A. Louvel, E. Baudin, J. Bertherat, Y. Chapuis, J.-M. Duclos, M. Schlumberger, et al. Molecular Markers and Long-Term Recurrences in a Large Cohort of Patients with Sporadic Adrenocortical Tumors Cancer Res., September 1, 2001; 61(18): 6762 - 6767. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lacroix, N. N'Diaye, J. Tremblay, and P. Hamet Ectopic and Abnormal Hormone Receptors in Adrenal Cushing's Syndrome Endocr. Rev., February 1, 2001; 22(1): 75 - 110. [Abstract] [Full Text] |
||||
![]() |
F. Wilkin, N. Gagné, J. Paquette, L. L. Oligny, and C. Deal Pediatric Adrenocortical Tumors: Molecular Events Leading to Insulin-Like Growth Factor II Gene Overexpression J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2048 - 2056. [Abstract] [Full Text] |
||||
![]() |
P. Mulatero, D. Schiavone, F. Fallo, F. Rabbia, C. Pilon, L. Chiandussi, L. Pascoe, and F. Veglio CYP11B2 Gene Polymorphisms in Idiopathic Hyperaldosteronism Hypertension, March 1, 2000; 35(3): 694 - 698. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Pilon, M. Pistorello, A. Moscon, G. Altavilla, U. Pagotto, M. Boscaro, and F. Fallo Inactivation of the p16 Tumor Suppressor Gene in Adrenocortical Tumors J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2776 - 2779. [Abstract] [Full Text] |
||||
![]() |
L. Barzon, C. Scaroni, N. Sonino, F. Fallo, A. Paoletta, and M. Boscaro Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 520 - 526. [Abstract] [Full Text] |
||||
![]() |
R. V. Lloyd, L. A. Erickson, L. Jin, E. Kulig, X. Qian, J. C. Cheville, and B. W. Scheithauer p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers Am. J. Pathol., February 1, 1999; 154(2): 313 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gicquel, M.-L. Raffin-Sanson, V. Gaston, X. Bertagna, P.-F. Plouin, M. Schlumberger, A. Louvel, J.-P. Luton, and Y. Le Bouc Structural and Functional Abnormalities at 11p15 Are Associated with the Malignant Phenotype in Sporadic Adrenocortical Tumors: Study on a Series of 82 Tumors J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2559 - 2565. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Latronico and G. P. Chrousos Adrenocortical Tumors J. Clin. Endocrinol. Metab., May 1, 1997; 82(5): 1317 - 1324. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |